Amicus Therapeutics (FOLD) Revenue & Revenue Breakdown
Amicus Therapeutics Revenue Highlights
Latest Revenue (Y)
$399.36M
Latest Revenue (Q)
$110.40M
Main Geography (Y)
Non-US
Amicus Therapeutics Revenue by Period
Amicus Therapeutics Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $399.36M | 21.30% |
| 2022-12-31 | $329.23M | 7.76% |
| 2021-12-31 | $305.51M | 17.11% |
| 2020-12-31 | $260.89M | 43.16% |
| 2019-12-31 | $182.24M | 99.72% |
| 2018-12-31 | $91.25M | 147.08% |
| 2017-12-31 | $36.93M | 644.86% |
| 2016-12-31 | $4.96M | 100.00% |
| 2015-12-31 | - | -100.00% |
| 2014-12-31 | $1.22M | 237.19% |
| 2013-12-31 | $363.00K | -98.03% |
| 2012-12-31 | $18.41M | -14.10% |
| 2011-12-31 | $21.43M | 2224.73% |
| 2010-12-31 | $922.00K | -98.57% |
| 2009-12-31 | $64.36M | 330.00% |
| 2008-12-31 | $14.97M | 738.96% |
| 2007-12-31 | $1.78M | 100.00% |
| 2006-12-31 | - | 100.00% |
| 2005-12-31 | - | 100.00% |
| 2004-12-31 | - | 100.00% |
| 2003-12-31 | - | - |
Amicus Therapeutics generated $399.36M in revenue during NA 2023, up 21.30% compared to the previous quarter, and up 437.67% compared to the same period a year ago.
Amicus Therapeutics Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-03-31 | $110.40M | -4.07% |
| 2023-12-31 | $115.08M | 11.19% |
| 2023-09-30 | $103.50M | 9.52% |
| 2023-06-30 | $94.50M | 9.54% |
| 2023-03-31 | $86.27M | -2.07% |
| 2022-12-31 | $88.10M | 7.84% |
| 2022-09-30 | $81.69M | 1.19% |
| 2022-06-30 | $80.73M | 2.56% |
| 2022-03-31 | $78.72M | -4.19% |
| 2021-12-31 | $82.15M | 3.28% |
| 2021-09-30 | $79.55M | 2.75% |
| 2021-06-30 | $77.41M | 16.58% |
| 2021-03-31 | $66.40M | -5.91% |
| 2020-12-31 | $70.57M | 4.65% |
| 2020-09-30 | $67.44M | 8.15% |
| 2020-06-30 | $62.35M | 3.02% |
| 2020-03-31 | $60.52M | 9.46% |
| 2019-12-31 | $55.29M | 13.38% |
| 2019-09-30 | $48.77M | 10.51% |
| 2019-06-30 | $44.13M | 29.62% |
| 2019-03-31 | $34.05M | 4.29% |
| 2018-12-31 | $32.64M | 58.50% |
| 2018-09-30 | $20.60M | -3.35% |
| 2018-06-30 | $21.31M | 27.63% |
| 2018-03-31 | $16.70M | 13.35% |
| 2017-12-31 | $14.73M | 35.45% |
| 2017-09-30 | $10.87M | 51.91% |
| 2017-06-30 | $7.16M | 71.70% |
| 2017-03-31 | $4.17M | 47.26% |
| 2016-12-31 | $2.83M | 33.10% |
| 2016-09-30 | $2.13M | 100.00% |
| 2016-06-30 | - | 100.00% |
| 2016-03-31 | - | 100.00% |
| 2015-12-31 | - | 100.00% |
| 2015-09-30 | - | 100.00% |
| 2015-06-30 | - | 100.00% |
| 2015-03-31 | - | 100.00% |
| 2014-12-31 | - | -100.00% |
| 2014-09-30 | $293.00K | -38.32% |
| 2014-06-30 | $475.00K | 4.17% |
| 2014-03-31 | $456.00K | 40.74% |
| 2013-12-31 | $324.00K | 730.77% |
| 2013-09-30 | $39.00K | 100.00% |
| 2013-06-30 | - | 100.00% |
| 2013-03-31 | - | 100.00% |
| 2012-12-31 | - | 100.00% |
| 2012-09-30 | - | -100.00% |
| 2012-06-30 | $10.64M | 36.83% |
| 2012-03-31 | $7.77M | 38.08% |
| 2011-12-31 | $5.63M | -2.90% |
| 2011-09-30 | $5.80M | 43.51% |
| 2011-06-30 | $4.04M | -32.28% |
| 2011-03-31 | $5.97M | 547.07% |
| 2010-12-31 | $922.00K | 100.00% |
| 2010-09-30 | - | 100.00% |
| 2010-06-30 | - | 100.00% |
| 2010-03-31 | - | -100.00% |
| 2009-12-31 | $49.48M | 907.04% |
| 2009-09-30 | $4.91M | -8.36% |
| 2009-06-30 | $5.36M | 16.39% |
| 2009-03-31 | $4.61M | 6.01% |
| 2008-12-31 | $4.34M | 18.94% |
| 2008-09-30 | $3.65M | -4.05% |
| 2008-06-30 | $3.81M | 20.47% |
| 2008-03-31 | $3.16M | 100.00% |
| 2007-12-31 | - | - |
Amicus Therapeutics generated $110.40M in revenue during Q1 2024, up -4.07% compared to the previous quarter, and up 125.32% compared to the same period a year ago.
Amicus Therapeutics Revenue Breakdown
Amicus Therapeutics Revenue Breakdown by Country
Annual Revenue by Country
| Country | Dec 23 | Dec 22 | Dec 21 | Dec 20 | Dec 19 |
|---|---|---|---|---|---|
| Non-US | $252.42M | $213.29M | $210.13M | $180.84M | $129.76M |
| UNITED STATES | $146.94M | $115.95M | $95.39M | $80.05M | $52.48M |
Amicus Therapeutics's latest annual revenue breakdown by geography, as of Dec 23: Non-US (63.21%), and UNITED STATES (36.79%).
Quarterly Revenue by Country
| Country | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-US | $73.03M | $71.91M | $65.70M | $57.38M | $57.44M | $54.09M | $51.47M | $53.19M | $54.54M | $56.93M | $53.91M | $53.73M | $45.55M | $49.38M | $47.16M | $41.55M | $42.75M | $39.48M | $33.36M | $31.95M |
| UNITED STATES | $37.38M | $43.18M | $37.80M | $37.13M | $28.83M | $34.01M | $30.22M | $27.54M | $24.18M | $25.22M | $25.64M | $23.68M | $20.85M | $21.19M | $20.28M | $20.81M | $17.77M | $15.82M | $15.41M | $12.18M |
Amicus Therapeutics's latest quarterly revenue breakdown by geography, as of Mar 24: Non-US (66.15%), and UNITED STATES (33.85%).
Amicus Therapeutics Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| INCY | Incyte | $3.70B | $1.04B |
| BMRN | BioMarin Pharmaceutical | $2.42B | $712.03M |
| ARGX | argenx SE | $1.23B | $401.00M |
| HRMY | Harmony Biosciences | $582.02M | $172.81M |
| RARE | Ultragenyx Pharmaceutical | $434.25M | $147.03M |
| FOLD | Amicus Therapeutics | $399.36M | $110.40M |
| DNLI | Denali Therapeutics | $330.53M | - |
| LEGN | Legend Biotech | $285.14M | $93.99M |
| BPMC | Blueprint Medicines | $249.38M | $138.16M |
| ARVN | Arvinas | $78.50M | $76.50M |
| AGIO | Agios Pharmaceuticals | $26.82M | $8.62M |
| RVMD | Revolution Medicines, Inc. Warrant | $11.58M | - |
| MREO | Mereo BioPharma Group | $10.00M | - |
| CYTK | Cytokinetics | $7.53M | $249.00K |
| CRNX | Crinetics Pharmaceuticals | $4.01M | $640.00K |
| INBX | Inhibrx | $1.80M | - |
| KRTX | Karuna Therapeutics | $654.00K | - |
| DAWN | Day One Biopharmaceuticals | - | $8.19M |
| DICE | DICE Therapeutics | - | - |
| DYN | Dyne Therapeutics | - | - |
| KURA | Kura Oncology | - | - |
| MLYS | Mineralys Therapeutics | - | - |
| EWTX | Edgewise Therapeutics | - | - |
FOLD Revenue FAQ
What is Amicus Therapeutics’s yearly revenue?
Amicus Therapeutics's yearly revenue for 2023 was $399.36M, representing an increase of 21.30% compared to 2022. The company's yearly revenue for 2022 was $329.23M, representing an increase of 7.76% compared to 2021. FOLD's yearly revenue for 2021 was $305.51M, representing an increase of 17.11% compared to 2020.
What is Amicus Therapeutics’s quarterly revenue?
Amicus Therapeutics's quarterly revenue for Q1 2024 was $110.4M, a -4.07% decrease from the previous quarter (Q4 2023), and a 27.97% increase year-over-year (Q1 2023). The company's quarterly revenue for Q4 2023 was $115.08M, a 11.19% increase from the previous quarter (Q3 2023), and a 30.63% increase year-over-year (Q4 2022). FOLD's quarterly revenue for Q3 2023 was $103.5M, a 9.52% increase from the previous quarter (Q2 2023), and a 26.70% increase year-over-year (Q3 2022).
What is Amicus Therapeutics’s revenue growth rate?
Amicus Therapeutics's revenue growth rate for the last 3 years (2021-2023) was 30.72%, and for the last 5 years (2019-2023) was 119.14%.